|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Female Sexual Dysfunction: Prescription Drug Pipeline Overview 2007 |
|
|
|
|
€ 3 040,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Juillet 2007 |
Taille du document : |
27 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (3) |
|
|
|
| 21 pages | Octobre 2006 | Anglais
|
|
|
| Main
focus: |
clinical trial,pharmaceutical,clinical trials,...,...
|
| Research
focus: |
market size and estimates,economy outlook |
| Geographic
focus: |
china,japan,india,indonesia,malaysia,singapore,... |
| |
|
|
|
|
| 21 pages | Septembre 2006 | Anglais
|
|
|
| Main
focus: |
clinical trial,clinical trials,toxicology,...
|
| Research
focus: |
market outlook,market size and estimates, |
| Geographic
focus: |
usa,canada,spain |
| |
|
|
|
|
| 40 pages | Mars 2004 | Anglais
|
|
|
| Main
focus: |
clinical trials,toxicology,pharmaceuticals,...,...
|
| Research
focus: |
market outlook,market definition, |
| Geographic
focus: |
usa,japan,united kingdom |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
The UK piling Market
40 pages | Mai 2002 |
This report will enable you to:Analyse the size of the UK market for piling between 1997 and 2006Quantify the size of the UK market for piling, 1997-2006, by technique: - bored - driven - embedded |
365,00 €
|
| |
| |
Healthcare In Southern Ireland
40 pages | Mai 2000 |
The Republic Of Ireland Presentation Includes:- The Structure Of The Health Service In The Republic Of Ireland- Capital Expenditure On Health Care In The Republic Of Ireland- Number Of Publicly Funded |
327,00 €
|
| |
| |
The Pharmaceutical Distribution Outlook 1998-2008
165 pages | Octobre 1998 |
Industry growth and consolidation means that pharmaceutical manufacturers are no longer geographically limited in their operations and now market their products globally, creating a vast commercia |
795,00 €
|
| |
| |
The Pharmacogenomics Outlook
174 pages | Août 2000 |
Pharmaceutical companies are coming under increasing pressure to increase the quality of their products, and optimize and accelerate drug discovery and development.
By identifying differenc |
955,00 €
|
| |
| |
Pharmaceutical Pricing Strategies 2000: Entering the new millennium
240 pages | Juin 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years.
Where once a company's freedom over pricing decisions was almost limitless, external pressure |
955,00 €
|
| |
| |
Healthcare In Wales
50 pages | Mai 2000 |
The Welsh Presentation Includes:- The Structure Of The NHS In Wales- Revenue Expenditure On Health Services In Wales- Number Of Hospital Units - Number Of Available Inpatient Beds- Number Of Occupied |
327,00 €
|
| |
| |
Healthcare: Germany
106 pages | Octobre 2000 |
Compare the changes in expenditure between the different healthcare sectors in Germany · Understand the main factors affecting demand for healthcare services in Germany · Examine the |
578,54 €
|
| |
| |
The CNS Outlook 2000
203 pages | Octobre 2000 |
The Central Nervous System (CNS) market has shown sustained growth in 1999 with the expansion continuing to be driven by several factors.A greater understanding of the neuropharmacological mechanisms |
955,00 €
|
| |
| |
Pharmaceutical Pricing Strategies
121 pages | Juillet 1998 |
Which pricing strategies will enable your company to maximise profitability? As healthcare cost-containment intensifies and pricing freedom is eroded, the need to develop new strategies to mainta |
795,00 €
|
| |
| |
The Japanese Pharmaceutical Market Outlook 2001
142 pages | Août 2001 |
Although Japan is the second largest pharmaceutical market in the world, it has traditionally been a relative 'no-go' area for pre-eminent Western drug companies.
Now, however, extensive cultur |
1 200,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Female Sexual Dysfunction: Prescription Drug Pipeline Overview 2007 |
|
|
Introduction
Female sexual dysfunction (FSD) affects an estimate 84 million women across the seven major pharmaceutical markets and represents a significant opportunity for investment. Despite its high prevalence, FSD is poorly understood and defined. Currently there is just one product approved for the treatment of FSD; P&G's Intrinsa (testosterone) is marketed in Germany, France and the UK.
Scope
Comprehensive overview of the FSD pipeline with focus on clinical candidates in development for FSD Analysis of the latest clinical trials results of FSD drug candidates in Phase I to III development Analysis of the challenges and opportunities facing products in Phase III and above with estimates of launch dates. Separation of drugs in development for different patient segments including hypoactive sexual desire disorder and female sexual arousal disorder
Highlights
Despite the relatively large patient population, currently there is just one approved drug treatment for FSD. There is much unmet need among patients and physicians and consequently Datamonitor believes there is an opportunity to develop this market to parallel to that of the multi-billion dollar male erectile dysfunction market While Intrinsa has benefited from first-to-market advantage, the drug suffers from several weaknesses that can be targeted by pipeline drug companies. Pipeline products can compete on safety, cost, efficiency, delivery, 'cosmetic elegance' and reduced skin irritation The FDA rejection of Intrinsa for FSD has left a big gap in the market. Depending on the outcome of ongoing clinical trials, there are several appealing inlicensing opportunities for larger companies wishing to unlock the potentially lucrative US market
Reasons to Purchase
Understand the placement of key compounds within the FSD development pipeline Identify challenges to be met and niches to be filled in the FSD market Assess novel mechanisms of action in the early pipeline and their potential for the treatment of FSD
|
|
ABOUT DATAMONITOR HEALTHCARE 2
About the Women's Health pharmaceutical analysis team 2
OVERVIEW 4
Introduction 4
Scope of this report 4
Pipeline overview highlights 4
Key reasons to read this report 5
Related reports 5
Disclaimer 6
|
|
|
PPLSEN
|
|
|
|
|
